COMBIVENT RESPIMAT Rx
Generic Name and Formulations:
Ipratropium bromide 20mcg, albuterol 100mcg (equivalent to 120mcg albuterol sulfate); per actuation; inhalation spray; CFC-free.
Boehringer Ingelheim Pharmaceuticals
Indications for COMBIVENT RESPIMAT:
COPD when a second aerosol bronchodilator is needed.
1 inh 4 times daily; max 6 inh/day.
Avoid excessive use. Discontinue if paradoxical bronchospasm occurs. Cardiovascular disorders. Arrhythmias. Hypertension. Diabetes. Hyperthyroidism. Seizure disorders. Sensitivity to sympthomimetic amines. Narrow angle glaucoma. GI or GU obstruction. Hepatic or renal disease. Pregnancy (Cat. C). Labor & delivery. Nursing mothers: not recommended.
Extreme caution within 2 weeks of MAOIs or tricyclic antidepressants (increased cardiovascular effects). Caution with other anticholinergics, sympathomimetics, drugs that lower serum potassium. Antagonized by beta-blockers.
Anticholinergic + beta-2 agonist.
Upper respiratory infection, nasopharyngitis, cough, bronchitis, headache, dyspnea; paradoxical bronchospasm, urinary retention, hypokalemia, hypersensitivity reactions, ocular effects.
Ipratropium bromide: renal.
Inhaler—4g (120 inh)
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA Fast-Tracks Treatment for Autism Spectrum Disorder
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics